Despite the broad range of potential treatment targets, an effective therapy does not exist for fibrosis or, for most other types of organ fibrosis. One explanation may relate to the fact that these cellular events are part of the normal wound healing process and as such must be effective, regulated and redundant. Bromodomain-containing chromatin readers represent a new and compelling epigenetic target class. We assessed PF-06405761 (PFI-1) and I-BET-151, as potential anti-fibrotic compounds. We will presents finding of, on a panel of fibrosis systems using human primary renal epithelial cell or small airway epithelial co-cultured with human primary lung fibroblasts, and a monoculture lung myofibroblast system. All systems stimulated with both TGFand TNF, we evaluated a range of fibrosis-related readouts as predictive biomarker, including ECM markers (aSMA, Cadherins, MMPs) and inflammatory markers (PAI-I, ITAC). Bromodomain inhibitors, emerging class of compounds, is highly active in BioMAP systems and they have a unique phenotype signature in the Fibrosis panel.